- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913158
Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in the Treatment of Symptomatic Internal Hemorrhoids
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, vehicle-controlled, multicenter, double blind study of Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in subjects with symptomatic internal hemorrhoids. Subjects will be randomly assigned in a 1:1 ratio to Test product or Vehicle, respectively.
Clinical evaluations will be performed at:
Visit 1/Day -3 (-1 day) to Day 1 Screening Visit 2/Day 1 Randomization (Start of Treatment) Visit 3/Day 8 (-1/+3 days) Interim Visit 4/Day 15 (-1/+3 days) End of Treatment / Early Termination Visit 5/ Day 28 (-1/+3 days)* 2 Weeks Post-Treatment/Follow-Up Phone Contact Safety will be assessed by monitoring adverse events (AEs) and clinically significant changes from Visit 1/Screening in laboratory values.
Number of Sites: Approximately 31 sites in the United States.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Clinical Research Associates
-
-
Florida
-
Sanford, Florida, United States, 32771
- IC Research
-
-
Michigan
-
Wyoming, Michigan, United States, 49519
- Gastro Associates of Western Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subjects with a diagnosis of symptomatic internal hemorrhoids will be selected to participate in the study.
- Eligible subjects will be males or non-pregnant, non-lactating, non-menstruating females; ≥ 18 years of age; with diagnosis of Grade I, II or III internal hemorrhoidal disease.
- For study entry the subject must have had anorectal bleeding during or after at least 2 of the 4 most recent attempted or successful bowel movements prior to Screening.
- Subject may also have one or more other symptoms: pain, itching or throbbing.
- At Visit 2/Day 1 (Randomization) subject must have recorded at least 2 instances of anorectal bleeding and no more than 1 incidence of no anorectal bleeding during attempted or successful bowel movements during the screening period between Visit 1/ Day -3 (Screening) and prior to Visit 2/Day 1 (Randomization).
Exclusion Criteria
- History of permanent full-thickness rectal prolapse.
- Current anal fissures and/or infective anal pathology.
- Previous history of surgery for anorectal disease (within 1 year) or any other anorectal procedures
- Subjects who are mentally incapacitated such that informed consent cannot be obtained.
- Clinically significant co-morbid condition.
- Diagnosis of Inflammatory Bowel Disease (IBD).
- Evidence or history of fecal incontinence.
- Clinically significant Laboratory values for hematology and chemistry .
- Subjects who have had oral, transdermal, or injectable steroid therapy within days from Visit 1/Screening.
- Presence of fissure or a fistula-in-ano, abscess, severe diverticular disease, polyps or colorectal adenoma or colorectal cancer, arteriovenous malformations, or any other pathological condition of the anus, colon or rectum other than symptomatic internal hemorrhoids which might be a potential cause of hematochezia.
- Clinically significant systemic disease.
- Pelvic radiation in the past or present.
- Use of any venotropic medications within 7 days from Visit 2/Day 1.
- Use of any anti-coagulant medications within 10 days from Visit 2/Day 1.
- Use of topical/anorectal corticosteroids for hemorrhoidal therapy within 7 days from Visit 2/Day 1.
- Use of topical/anorectal medicated hemorrhoidal therapy within 24 hours from Visit 2/Day 1.
- Unable to cease use of OTC or prescription medications for treatment of hemorrhoidal disease during study period.
- Immunocompromised subjects.
- Known hypersensitivity or allergies to Hydrocortisone Acetate or any component of the IP (in any dosage form).
- Use of any investigational drug or investigational device within 30 days prior to randomization.
- Previous participation in this study.
- Subject consumes excessive alcohol, abuses drugs, or has a condition that could compromise the subjects ability to comply with study requirements.
- Subjects unable to have a spontaneous bowl movement every day prior to randomization.
- Rectal varicies or portal hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo suppository
Hydrogenated palm kernel oil suppositories
|
Hydrogenated palm kernel oil suppositories
Other Names:
|
Active Comparator: Anucort-HC, 25 Mg Rectal Suppository
Hydrocortisone Acetate suppositories
|
Hydrocortisone acetate suppositories
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bleeding Cessation
Time Frame: Up to 18 days
|
The primary endpoint is bleeding cessation defined as cessation of anorectal bleeding associated with bowel movements or attempted bowel movements which does not recur after cessation for the remainder of the study period.
The proportion of subjects with bleeding cessation using Anucort HCTM 25mg Rectal Suppositories will be compared statistically with the proportion of subjects using placebo.
|
Up to 18 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement in the Severity Score of Pain
Time Frame: Up To 18 days
|
Improvement in the Severity Score of Pain on the Visual Analogue Scale (VAS) from baseline to Visit 3/Day 8 and Visit 4 (End of Treatment)
|
Up To 18 days
|
Improvement in the Severity Score of Itching
Time Frame: Up to 18 days
|
Improvement in the Severity Score of Itching from baseline to Visit 3/Day 8 and Visit 4 (End of Treatment)
|
Up to 18 days
|
Improvement in the Severity Score of Throbbing
Time Frame: Up to 18 days
|
Improvement in the Severity Score of Throbbing to from baseline to Visit 3/Day 8 and Visit 4/Day 15 (End of Treatment)
|
Up to 18 days
|
Improvement in the Investigator Assessment
Time Frame: Up to 18 days
|
Improvement in the Investigator Assessment
|
Up to 18 days
|
Improvement in the Subject Global Assessment
Time Frame: Up to 18 days
|
Improvement in the Subject Global Assessment
|
Up to 18 days
|
Improvement in Severity of Bleeding
Time Frame: Up To 18 days
|
Improvement in the severity of Bleeding from baseline to Visit 3/Day 8 and Visit 4 (End of Treatment)
|
Up To 18 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Allan G Coates, DO, Gastro Associates of Western Michigan
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRG-NY-13-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Internal Hemorrhoids
-
Xinhua Hospital, Shanghai Jiao Tong University...The First Affiliated Hospital of Zhengzhou University; Shanghai Ninth People... and other collaboratorsUnknownGrade/Stage I Hemorrhoids | Prolapsed Grade II Internal Haemorrhoid | Prolapsed Grade III Internal HaemorrhoidChina
-
Ventrus Biosciences, IncTerminatedInternal HemorrhoidsUnited States
-
Nivagen Pharmaceuticals Inc.CompletedInternal HemorrhoidsUnited States, India
-
Universidade do PortoCompletedHemorrhoids, InternalPortugal
-
Medtronic - MITGCompletedHemorrhoids, InternalUnited States
-
Universitätsklinikum Hamburg-EppendorfCompletedInternal Hemorrhoids
-
Proctos KliniekRecruitingRectal Diseases | Hemorrhoids | PROM | Hemorrhoids, InternalNetherlands
-
Konya Meram State HospitalCompleted
-
Developeration ABRecruitingSCI-Pex Study - Safety and Performance of PexyEazy®, a Device for Treatment of Hemorrhoids (SCI-Pex)Gastrointestinal Diseases | Rectal Diseases | Hemorrhoids | Suture; Complications, Infection or Inflammation | Hemorrhoids, InternalSweden
-
Renmin Hospital of Wuhan UniversityThe First Affiliated Hospital of Nanchang University; Zhejiang University; Hubei... and other collaboratorsNot yet recruitingHemorrhoids | Hemorrhoid Prolapse | Hemorrhoid | Hemorrhoid Bleeding | Hemorrhoid Pain | Hemorrhoids InternalChina
Clinical Trials on Placebo suppository
-
Laboratoires Techni PharmaCompleted
-
Laboratoires Techni PharmaCompleted
-
University of New MexicoWithdrawnInterstitial Cystitis | Bladder Pain SyndromeUnited States
-
RDD Pharma LtdWithdrawn
-
Seed HealthActive, not recruitingVaginal Personal CareUnited States
-
Peking University Shenzhen HospitalRecruiting
-
RDD Pharma LtdCompletedFecal IncontinenceIsrael
-
Padagis LLCCompleted
-
Microbicide Trials NetworkNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedHIV PreventionUnited States, Malawi, Peru, South Africa, Thailand
-
Hatem AbuHashimUnknownVulvovaginal Candidiasis